NCT06377072已完成3 期
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Shenqi Sherong Pill in Cervical Spondylotic Myelopathy (Qi Deficiency, Blood Stasis and Kidney Deficiency Type)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 428
- 试验地点
- 1
- 主要终点
- Change in Modified Japanese Orthopaedic Association (mJOA) score
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration.
详细描述
- Trial Design： This is a multi-center, randomized, double-blind, placebo-controlled phase III study，which plans to enroll 428 participants who will be randomized to Shenqi Sherong pill group or placebo control group. The Modified Japanese Orthopaedic Association (mJOA) Score combined with the changes of clinical symptoms and syndrome score are used as the validity index. The laboratory examination and incidence of adverse events are used as the safety index.
- Therapeutic schedule： Participants will be provided with neck braces and recommended to wear them daily or outdoors along with health education. Participants will be treated with the investigational drug (Shenqi Sherong Pill or placebo ) by taking two bags each time, three times a day at half an hour after breakfast, lunch and dinner for 6 weeks, with a 2-week follow-up after withdrawal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants can only be selected if they meet all the inclusion criteria
- •Age 18-75 years old (including 18 and 75 years old), gender unlimited;
- •Accord with Western medicine diagnosis standards of Cervical Spondylotic Myelopathy;
- •Accord with Chinese medicine diagnosis standards of qi deficiency, blood stasis and kidney deficiency type;
- •The disease classification was mild or moderate (13 ≤mJOA score ≤15);
- •X-ray examination of six cervical vertebrae (frontal, lateral, hyperextension and flexion lateral and double oblique) indicates cervical degenerative changes, while MRI examination indicates spinal cord compression;
- •The first diagnosis of Cervical Spondylotic Myelopathy within 3 months; for those diagnosed for more than 3 months, the investigator needs to determine that the condition is basically stable;
- •Participants voluntarily participate in this experiment and sign an informed consent.
- •Note: 1) CT examination is determined by the investigator according to the specific conditions of participants. 2) Imaging materials of MRI, X-ray(frontal, lateral, hyperextension and flexion and double oblique), CT examination within 3 months from the 3A Grade hospital can be accepted ; 3) If the laboratory tests and 12-lead electrocardiogram are completed in the research center on the same day before the participant signing an informed consent, the examination can not be repeated after the investigator judging.
排除标准
- •Participants should be excluded if they meet any one exclusion criteria :
- •The use of long-acting hormone drugs within 1 week before screening, or the last drug use is less than 7 half-lives, or Traditional Chinese Medicine, drugs with no marked half-life, physical therapy, etc. is less than 3 days before screening for the treatment of this disease;
- •Participants with obvious concurrent syndrome or complication (such as Hypertension after taking antihypertensive drugs who systolic pressure ≥160mmHg, or diastolic pressure ≥100mmHg , or Diabetes after taking antidiabetic drugs who fasting blood glucose ≥10.0mmol/L and so on);
- •MRI examination shows the degree of spinal stenosis is 1/2 or more, or the spinal cord compression caused by cervical spondylosis is three or more segments;
- •Participants with severe hand muscle atrophy, or spasms, or is difficult to walk independently, or urinary dysfunction;
- •Participants with cervical spine fracture, or congenital deformity of cervical spine, or ossification of ligamentum flavum, or ossification of posterior longitudinal ligament, or with neurological diseases such as lateral sclerosis and multiple sclerosis;
- •Participants with visual analogue scale(VAS) score >7 points (7 points is defined as the distance between the left end and the mark location equal to 7.0cm);
- •Participants with severe heart disease, such as myocardial infarction, unstable angina pectoris, Ⅲ to Ⅳ congestive heart failure and severe arrhythmia according to New York Heart Association (NYHA),or with severe liver and kidney diseases, or with abnormal liver and kidney function tests (Alanine aminotransferase or Aspartate aminotransferase ≥ 1.5 times the upper limit of normal, or creatinine clearance> the upper limit of normal); or with severe lung disease such as chronic bronchitis, asthma, chronic obstructive pulmonary disease(COPD) and other acute episodes;
- •Participants with cerebral infarction and serious mental disorders;
- •Woman in lactation, pregnancy, or planned pregnancy;
- •Participant is allergic constitution or known to be allergic to the components of the investigational drug;
- •Participants have participated or are participating in other clinical trials within 3 months;
- •Participants are judged unsuitable for participation by the investigators in the study.
- •Note: 1) If examination or efficacy index score of visit 1 and visit 2 is overlapping item, the baseline standard is based on visit 2; 2) Participant who has the abnormal laboratory examination items during screening can be arranged for retest, whether to be enrolled or not will be comprehensively evaluated by the investigators.
研究组 & 干预措施
Shenqi Sherong Pill
Experimental
6g per bag
干预措施: Shenqi Sherong Pill (Drug)
Placebo
Placebo Comparator
6g per bag
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Modified Japanese Orthopaedic Association (mJOA) score
时间窗: 42±2 days
Change in Modified Japanese Orthopaedic Association (mJOA) score (on a scale from 0 to 18, with lower scores indicating greater disability) from baseline at Day 42 after administration; the mJOA which is a clinician administered scale to evaluate four clinical dimensions; motor dysfunction score for upper and lower extremities, sensation loss and sphincter dysfunction.
次要结局
- Change in mJOA score(14±2 days, 28±2 days, 56±2 days)
- Change in numbness (or pain) scores from the chest to the toes(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Change in Motor dysfunction of the upper extremities of mJOA score(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Change in sensation of mJOA score(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Changes in pain or stiffness score for neck and shoulder(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Change in chest tightness score(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Changes in hand and arm numbness scores(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Change in Traditional Chinese medicine (TCM) syndrome integrality(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Proportion of participants with at least 1 grade decline in Nurick grades(14±2 days, 28±2 days, 42±2 days or 56±2 days)
- Change in TCM syndrome score(14±2 days, 28±2 days, 42±2 days or 56±2 days)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie CapsuleFibrocystic Disease of BreastNCT02929420First Affiliated Hospital Xi'an Jiaotong University600
Unknown
4 期
Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina PectorisCoronary Heart DiseaseStable AnginaNCT04270279Guang'anmen Hospital of China Academy of Chinese Medical Sciences120
已完成
1 期
A Study of Qishenyiqi Dripping Pills in Healthy ParticipantsHealthy ParticipantsNCT04471298Tasly Pharmaceutical Group Co., Ltd36
已完成
3 期
Efficacy and Safety of Shinbaro CapsuleOsteoarthritisNCT01535417Green Cross Corporation198
已完成
4 期
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary ArteryIschemia With Non-Obstructive Coronary ArteryX Syndrome, AnginaCoronary Heart DiseaseAngina PectorisNCT04897126Shanghai Hutchison Pharmaceuticals Limited240